PFIZER/EISAI ARICEPT SALES ARE $75 MIL. FOR FIRST HALF OF YEAR; ZYRTEC SALES DOUBLE IN SECOND QUARTER; MERCK FOSAMAX U.S. SALES ARE $83 MIL. IN QUARTER
Executive Summary
Pfizer/Eisai's Alzheimer's disease therapy Aricept registered $42 mil. in worldwide trade sales during the second quarter of 1997, Pfizer reported July 15. First quarter sales following launch were $33 mil.